Reuters logo
in 7 months
BRIEF-Catalyst Biosciences secures all rights to manufacturing process for Marzeptacog Alfa from Wyeth LLC, a wholly-owned subsidiary of Pfizer
December 19, 2016 / 1:16 PM / in 7 months

BRIEF-Catalyst Biosciences secures all rights to manufacturing process for Marzeptacog Alfa from Wyeth LLC, a wholly-owned subsidiary of Pfizer

1 Min Read

Dec 19 (Reuters) - Catalyst Biosciences Inc :

* Catalyst Biosciences Inc - drug product fill-finish manufacturing services agreement for marzeptacog alfa (activated) for clinical trial applications

* Catalyst Biosciences Inc - has secured all rights to manufacturing process for Marzeptacog Alfa from Wyeth LLC, a wholly-owned subsidiary of Pfizer

* Catalyst Biosciences Inc - has signed a drug product fill-finish manufacturing services agreement with symbiosis pharmaceutical services limited

* Catalyst Biosciences Inc - prepared to initiate an efficacy study in 2017 for marzeptacog alpha (activated) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below